Rising Autism Cases and Acetaminophen Concerns

This year, Health and Human Services Secretary Robert F. Kennedy Jr. raised concerns about an increase in autism diagnoses in the U.S. He stated, “We’re doing this to our kids; we need to put an end to that.”

Kennedy referred to a study indicating that for children born in 2014, the prevalence of autism spectrum disorder (ASD) among 8-year-olds is now 1 in 31. He noted that American boys are at “extreme risks,” pointing out a 1 in 20 chance of being diagnosed in general, while in California, that risk is heightened to 1 in 12.5.

Moreover, Kennedy recalled a previous statement from President Donald Trump, who, back in April, indicated that the cause of the autism increase would be identified by September, which could lead to solutions for the issue.

A recent study published in the peer-reviewed journal BMC Environmental Health might provide valuable insights into factors contributing to autism. Researchers from various prestigious institutions, including Harvard and UCLA, reviewed a total of 46 well-structured studies involving over 100,000 participants. These studies examined the correlation between autism, temperamental disorders, and neurodevelopmental disorders.

“The research team’s findings strengthen evidence of connection and raise concerns about current clinical practice,” the report claimed.

Acetaminophen—commonly marketed as Tylenol in both the U.S. and Canada—is widely used as a pain and fever reducer during pregnancy, with more than half of pregnant women globally reportedly using it. Among the 27 studies analyzed, many identified a significant connection between prenatal acetaminophen exposure and neurodevelopmental disorders (NDDs).

The findings revealed that most studies showed a positive association between the drug’s use during pregnancy and risks of attention deficit hyperactivity disorder (ADHD), ASD, and other NDDs in children. They also noted that acetaminophen crosses the placental barrier efficiently, reaching fetal circulation levels similar to those in the mother within about an hour after ingestion.

• It is metabolized via CYP2E1, an enzyme found in the fetal brain, placenta, and lungs, producing toxic byproducts.
• It impacts the prostaglandin and endocannabinoid pathways essential for prenatal neurodevelopment.
• Animal studies suggested it increases oxidative stress markers in the fetal brain, which is linked to neurodevelopmental disorders.
• It has the potential to directly disrupt hormone-related processes, affecting neurodevelopment and inducing damage to the placenta.

Dr. Diddier Prada, from the Icahn School of Medicine at Mount Sinai, stated, “Our findings show that high-quality studies are likely to link prenatal acetaminophen exposure to an increased risk of autism and ADHD.” Even minor risk increments could significantly impact public health, he emphasized.

While the research does not assert that acetaminophen directly causes neurodevelopmental disorders, it does indicate that these findings amplify concerns surrounding current medical practices.

The medical community has long scrutinized the use of acetaminophen during pregnancy. In a consensus statement from United Nations specialists published in September 2021, it was noted that both experimental and epidemiological studies suggest prenatal acetaminophen exposure can alter fetal development, potentially increasing the risks for various neurodevelopmental and reproductive issues.

HHS spokesperson Emily Hilliard remarked that the department prefers not to comment on external research but reiterated their commitment to guiding science-based actions under Secretary Kennedy’s leadership.

In response to the study, a representative from Kenvue, the company behind Tylenol, emphasized that consumer safety is paramount, asserting that current studies do not establish a causal link between acetaminophen use during pregnancy and fetal development problems. They pointed out that regulatory bodies like the FDA continue to recognize its safety when used as directed during pregnancy.

However, some critiques surfaced regarding the motivations behind the research, indicating a potential bias given that two authors are involved in ongoing litigation against Tylenol regarding its association with autism.

One of the researchers from Harvard, Dr. Andrea Bacarelli, has been designated as an expert in ongoing legal proceedings concerning this issue.